Absence of galectin-3 immunostaining in fine-needle aspiration cytology specimens from papillary thyroid carcinoma is associated with favorable pathological indices

Thyroid

Volumn 22, Issue 12, 2012, Pages 1244-1250

  Kim, Eun Sook ^a   Lim, Dong Jun ^a   Lee, Kyungji ^a   Jung, Chan Kwon ^a   Bae, Ja Seong ^a   Jung, So Lyung ^a   Baek, Ki Hyun ^a   Lee, Jong Min ^a   Moon, Sung Dae ^a   Kang, Moo Il ^a   Cha, Bong Yun ^a   Lee, Kwang Woo ^a   Son, Ho Young ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 3; THYROGLOBULIN; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; ASPIRATION CYTOLOGY; CANCER INVASION; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ECHOGRAPHY; FOLLOW UP; FREE THYROXINE INDEX; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NECK DISSECTION; NEEDLE BIOPSY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID NODULE; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TUMOR CELL; TUMOR VOLUME;

ADULT; AGED; BIOPSY, FINE-NEEDLE; CARCINOMA; FEMALE; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS;

EID: 84870792879     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2011.0166     Document Type: Article

References (35)

1. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, Rothman N 2009 International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes 20:525-531.
2. Leenhardt L, Grosclaude P, Chri-Challine L 2004 Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 14:1056-1060.
3. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167.
4. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer 83:2638-2648.
5. Gilliland FD, Hunt WC, Morris DM, Key CR 1997 Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79:564-573.
6. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050-1057.
7. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR 1998 Prospective multicenter study of thyrois]carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83:1012-1021.
8. Califice S, Castronovo V, Van Den Brle F 2004 Galectin-3 and cancer (Review). Int J Oncol 25:983-992.
9. Bartolazzi A, Gasbarri A, Papotti M, Bussolati G, Lucante T, Khan A, Inohara H, Marandino F, Orlandi F, Nardi F, Vecchione A, Tecce R, Larsson O 2001 Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 357:1644-1650.
10. Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, Palestini N, Ghigo E, Papotti M, Bussolati G, Martegani MP, Pantellini F, Carpi A, Giovagnoli MR, Monti S, Toscano V, Sciacchitano S, Pennelli GM, Mian C, Pelizzo MR, Rugge M, Troncone G, Palombini L, Chiappetta G, Botti G, Vecchione A, Bellocco R 2008 Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol 9:543-549.
11. Franco C, Martnez V, Allamand JP, Medina F, Glasinovic A, Osorio M, Schachter D 2009 Molecular markers in thyroid fine-needle aspiration biopsy: a prospective study. Appl Immunohistochem Mol Morphol 17:211-215.
12. Raz A, Meromsky L, Zvibel I, Lotan R 1987 Transformationrelated changes in the expression of endogenous cell lectins. Int J Cancer 39:353-360.
13. Raz A, Lotan R 1987 Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis. Cancer Metastasis Rev 6:433-452.
14. Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M 2008 Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation. Hum Pathol 39:1656-1663.
15. Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S, Sueyoshi K, Aikou T, Sato E 2000 Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 31:428-433.
16. Torregrossa L, Faviana P, Camacci T, Materazzi G, Berti P, Minuto M, Elisei R, Vitti P, Miccoli P, Basolo F 2007 Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type. Hum Pathol 38:1482-1488.
17. Barnes L, Eveson JW, Reichart P, Sidransky D (eds) 2005 World Health Organization classification of tumours. Pathology and genetics of head and neck tumours. IARC Press, Lyon, France.
18. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) 2010 AJCC Cancer Staging Manual, 7th ed. Springer-Verlag, New York.
19. Xing M 2010 Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 321:86-93.
20. Sapio MR, Guerra A, Posca D, Limone PP, Deandrea M, Motta M, Troncone G, Caleo A, Vallefuoco P, Rossi G, Fenzi G, Vitale M 2007 Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma. Endocr Relat Cancer 14: 1089-1097.
21. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A 2009 BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56:89-97.
22. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SC, Hong SJ, Shong YK 2005 The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 63:588-593.
23. Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A, Kubo T 1999 Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 85:2475-2484.
24. Rossi ED, Raffaelli M, Minimo C, Mule A, Lombardi CP, Vecchio FM, Fadda G 2005 Immunocytochemical evaluation of thyroid neoplasms on thin-layer smears from fine-needle aspiration biopsies. Cancer 105:87-95.
25. Xu XC, el-Naggar AK, Lotan R 1995 Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 147:815-822.
26. Tü rköz HK, Oksz H, Yurdakul Z, Ozcan D 2008 Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr Pathol 19:92-96.
27. van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, Liu FT, Cooper DN, Pieters C, Sobel ME, Castronovo V 1996 Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol 27:1185-1191.
28. Cvejic D, Savin S, Golubovic S, Paunovic I, Tatic S, Havelka M 2000 Galectin-3 and carcinoembryonic antigen expression in medullary thyroid carcinoma: possible relation to tumour progression. Histopathology 37:530-535.
29. Faggiano A, Talbot M, Lacroix L, Bidart JM, Baudin E, Schlumberger M, Caillou B 2002 Differential expression of galectin-3 in medullary thyroid carcinoma and C-cell hyperplasia. Clin Endocrinol (Oxf) 57:813-819.
30. Takenaka Y, Fukumori T, Raz A 2004 Galectin-3 and metastasis. Glycoconj J 19:543-549.
31. Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, Raz A 2000 Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 156:899-909.
32. O'Driscoll L, Linehan R, Liang YH, Joyce H, Oglesby I, Clynes M 2002 Galectin-3 expression alters adhesion, motility and invasion in a lung cell line (DLKP), in vitro. Anticancer Res 22:3117-3125.
33. Mourad-Zeidan A, Melnikova VO, Wang H, Raz A, Bar-Eli M 2008 Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry. Am J Pathol 173:1839-1852.
34. Lin C, Whang E, Donner DB, Jiang X, Price BD, Carothers AM, Delaine T, Leffler H, Nilsson UJ, Nose V, Moore FD, Ruan DT 2009 Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol Cancer Res 7:1655-1662.
35. Jung C, Lee A, Jung E, Choi Y, Jung S, Lee K 2008 Split sample comparison of a liquid-based method and conventional smears in thyroid fine needle aspiration. Acta Cytol 52:313-319.